Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 7.8%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 75,400 shares, a decline of 7.8% from the May 31st total of 81,800 shares. Based on an average daily trading volume, of 653,500 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Avalo Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Affinity Asset Advisors LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter worth approximately $218,000. Ikarian Capital LLC acquired a new position in Avalo Therapeutics in the 1st quarter valued at approximately $1,015,000. Finally, Acadian Asset Management LLC purchased a new stake in Avalo Therapeutics in the 3rd quarter worth approximately $34,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Oppenheimer upgraded shares of Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, April 16th.

Avalo Therapeutics Trading Down 2.8 %

Avalo Therapeutics stock traded down $0.35 during midday trading on Tuesday, reaching $12.26. The stock had a trading volume of 4,204 shares, compared to its average volume of 356,995. Avalo Therapeutics has a twelve month low of $3.95 and a twelve month high of $95.52. The firm’s fifty day simple moving average is $12.32 and its two-hundred day simple moving average is $9.53.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, May 13th. The company reported ($5.98) EPS for the quarter, missing the consensus estimate of ($1.18) by ($4.80). Avalo Therapeutics had a negative return on equity of 1,439.87% and a negative net margin of 1,639.50%. Research analysts forecast that Avalo Therapeutics will post -0.91 EPS for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.